Peripheral opioid receptor agonists for analgesia: A comprehensive review

Nalini Vadivelu, MD; Sukanya Mitra, MD; Roberta L. Hines, MD

doi:10.5055/jom.2011.0049

Authors

Nalini Vadivelu, MD
Sukanya Mitra, MD
Roberta L. Hines, MD

DOI:

https://doi.org/10.5055/jom.2011.0049

Keywords:

peripheral opioid receptors, peripheral opioid agonists, peripheral mu-/kappa-/delta-opioid, receptor agonists, inflammatory pain, neuropathic pain

Abstract

Background: It is established that opioid receptors are present in the dorsal root ganglia and the central as well as peripheral terminals of primary afferent neurons. Now, it has been shown that peripheral terminals of afferent nerves can be the sites of the intrinsic modulation of nociception and that opioid analgesia can be mediated by peripheral opioid receptors as well.
Aim: This review focuses on two areas: the first on describing the peripheral opioidergic system, and the second on the review of the current state of development of peripherally active opioid receptor agonists with their potential clinical applications.
Methods: Online and manual search using key words such as peripheral opioid receptors, peripheral (or peripherally restricted) opioid agonists, and peripheral mu-, kappa-, and delta-opioid receptor agonists, followed by full-text access and further cross-referencing.
Results: The obvious theoretical advantage of using these molecules is that analgesia is achieved while avoiding the bothersome-to-dangerous centrally mediated adverse effects of centrally acting opioids. Molecules known for their central action (eg, morphine) have been used in peripheral tissues (joints, bone, teeth) with reasonable but varied success. Over the last 10-15 years, several molecules with peripherally restricted opioid agonist activity have been developed and several more are in the “clinical pipeline.” Although none is available as an approved medication till date, a few (eg, the peripherally restricted kappa-agonist FE200665, also known as CR665) have completed phase I clinical trials and currently in phase II. Others such as loperamide, which is approved for use as an antidiarrheal drug, have been found to be variably useful as a peripherally acting opioid analgesic.
Conclusions: Substantive research is currently underway and this is an exciting research area for both basic and applied clinical fields. Various ways to enhance peripheral opioid analgesia are suggested.

Author Biographies

Nalini Vadivelu, MD

Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut.

Sukanya Mitra, MD

Department of Anaesthesia and Intensive Care, Government Medical College and Hospital, Chandigarh, India.

Roberta L. Hines, MD

Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut.

References

Ide S, Sakano K, Seki T, et al.: Endomorphin-1 discriminates the mu-opioid receptor from the delta- and kappa-opioid receptors by recognizing the difference in multiple regions. Jpn J Pharmacol. 2000; 83(4): 306-311.

Tegeder I, Meier S, Burian M, et al.: Peripheral opioid analgesia in experimental human pain models. Brain. 2003; 126 (Part 5): 1092-1102.

Lamotte C, Pert C, Snyder S: Opiate receptor binding in primate spinal cord: Distribution and changes after dorsal root section. Brain Res. 1976; 112(2): 407-412.

Fields H, Emson P, Leigh B, et al.: Multiple opiate receptor sites on primary afferent fibres. Nature. 1980; 284(5754): 351-353.

Hassan AH, Ableitner A, Stein C, et al.: Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience. 1993; 55(1): 185-195.

Antonijevic I, Mousa SA, Schafer M, et al.: Perineurial defect and peripheral opioid analgesia in inflammation. J Neurosci. 1995; 15(1, Part 1): 165-172.

Kobal G: Pain-related electrical potentials of the human nasal mucosa elicited by chemical stimulation. Pain. 1985; 22(2): 151-163.

Inturrisi CE: Clinical pharmacology of opioids for pain. Clin J Pain. 2002; 18(4 Suppl): S3-S13.

Stein C: The control of pain in peripheral tissues by opioids. N Engl J Med. 1995; 332(25): 1685-1690.

Stein C, Millan MJ, Shippenberg TS, et al.: Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther. 1989; 248(3): 1269-1275.

Perrot S, Guilbaud G, Kayser V: Effects of intraplantar morphine on paw edema and pain-related behaviour in a rat model of repeated acute inflammation. Pain. 1999; 83(2): 249-257.

Kolesnikov YA, Jain S, Wilson R, et al.: Peripheral morphine analgesia: Synergy with central sites and a target of morphine tolerance. J Pharmacol Exp Ther. 1996; 279(2): 502-506.

Stein C, Lang LJ: Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol. 2009; 9: 3-8.

Yaksh T: Substance P release from knee joint afferent terminals: Modulation by opioids. Brain Res. 1988; 458(2): 319-324.

Yaksh T, Jessell T, Gamse R, et al.: Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo. Nature. 1980; 286(5769): 155-157.

Werz M, MacDonald R: Opioid peptides selective for muand delta-opiate receptors reduce calcium-dependent action potential duration by increasing potassium conductance. Neurosci Lett. 1983; 42(2): 173-178.

Schroeder J, Fischbach P, Zheng D, et al.: Activation of mu opioid receptors inhibits transient high- and low-threshold Ca2+ currents, but spares a sustained current. Neuron. 1991; 6(1): 13-20.

Vetter I, Wyse B, Monteith G, et al.: The mu opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway. Mol Pain. 2006; 2: 22.

DeHaven-Hudkins D, Burgos L, Cassel J, et al.: Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther. 1999; 289(1): 494-502.

Clark C, Halfpenny P, Hill R, et al.: Highly selective kappa opioid analgesics. Synthesis and structure-activity relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide and N-[(2-aminocyclohexyl)aryloxy]acetamide derivatives. J Med Chem. 1988; 31(4): 831-836.

Barber A, Gottschlich R: Opioid agonists and antagonists: An evaluation of their peripheral actions in inflammation. Med Res Rev. 1992; 12(5): 525-562.

Stein A, Helmke K, Szopko C, et al.: Intra-articular morphine versus steroid administration to the acutely painful joint in gonarthrosis and arthritis. Dtsch Med Wochenschr. 1996; 121(8): 255.

Barber A, Gottschlich R: Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs. 1997; 6(10): 1351-1368.

Bakshi R, Ni R, Faden A: N-Methyl-D-aspartate (NMDA) and opioid receptors mediate dynorphin-induced spinal cord injury: Behavioral and histological studies. Brain Res. 1992; 580(1-2): 255-264.

Laughlin T, Vanderah T, Lashbrook J, et al.: Spinally administered dynorphin A produces long-lasting allodynia: Involvement of NMDA but not opioid receptors. Pain. 1997; 72(1-2): 253-260.

Machelska H, Pflüger M, Weber W, et al.: Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther. 1999; 290(1): 354-361.

Carr DJ, DeCosta BR, Jacobson AE, et al.: Enantioselective kappa opioid binding sites on the macrophage cell line, P388d1. Life Sci. 1991; 49(1): 45-51.

Selley DE, Breivogel CS, Childers SR: Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: Increase in opioid agonist efficacy by decreased inactivation of G proteins. Mol Pharmacol. 1993; 44(4): 731-741.

Allescher HD, Storr M, Piller C, et al.: Effect of opioid active therapeutics on the ascending reflex pathway in the rat ileum. Neuropeptides. 2000; 34(3-4): 181-186.

Hanks GW, Conno F, Cherny N, et al.: Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer. 2001; 84(5): 587-593.

Sproule BA, Busto UE, Somer G, et al.: Characteristics of dependent and nondependent regular users of codeine. J Clin Psychopharmacol. 1999; 19(4): 367-372.

Danzebrink RM, Green SA, Gebhart GF: Spinal mu and delta, but not kappa, opioid-receptor agonists attenuate responses to noxious colorectal distension in the rat. Pain. 1995; 63(1): 39-47.

Diop L, Riviere PJ, Pascaud X, et al.: Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine (correction of fetodozine) on the duodenal pain reflex inrat. Eur J Pharmacol. 1994; 271(1): 65-71.

Stein C, Schafer M, Machelska H: Attacking pain at its source: New perspectives on opioids. Nat Med. 2003; 9(8): 1003-1008.

Dapoigny M, Abitbol JL, Fraitag B: Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci. 1995; 40(10): 2244-2249.

Read NW, Abitbol JL, Bardhan KD, et al.: Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut. 1997; 41(5): 664-668.

Bredenoord AJ, Chial HJ, Camilleri M, et al.: Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol. 2003; 1(4): 264-272.

Minami M, Maekawa K, Yabuuchi K, et al. Double in situ hybridization study on coexistence of mu-, delta- and kappa-opioid receptor mRNAs with preprotachykinin A mRNA in the rat dorsal root ganglia. Brain Res Mol Brain Res. 1995; 30(2): 203-210.

Su X, Wachtel RE, Gebhart GF: Mechanosensitive potassium channels in rat colon sensory neurons. J Neurophysiol. 2000; 84(2): 836-843.

Gebhart GF: Peripheral contributions to visceral hyperalgesia. Can J Gastroenterol. 1999; 13 (Suppl A): 37A-41A.

Bonaz B, Riviere PJ, Sinniger V, et al.: Fedotozine, a kappaopioid agonist, prevents spinal and supra-spinal Fos expression induced by a noxious visceral stimulus in the rat. Neurogastroenterol Motil. 2000; 12(2): 135-147.

Barquist E, Zinner M, Rivier J, et al.: Abdominal surgeryinduced delayed gastric emptying in rats: Role of CRF and sensory neurons. Am J Physiol. 1992; 262(4, Part 1): G616-G620.

Dubois A, Weise VK, Kopin IJ: Postoperative ileus in the rat: Physiopathology, etiology and treatment. Ann Surg. 1973; 178(6): 781-786.

Holzer P: Capsaicin-sensitive afferent neurones and gastrointestinal propulsion in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1986; 332(1): 62-65.

Ness TJ, Metcalf AM, Gebhart GF: A psychophysiological study in humans using phasic colonic distension as a noxious visceral stimulus. Pain. 1990; 43(3): 377-386.

Delgado-Aros S, Chial H, Camilleri M, et al.: Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol. 2003; 284(4): G558-G566.

Coggeshall R, Zhou S, Carlton S: Opioid receptors on peripheral sensory axons. Brain Res. 1997; 764(1-2): 126-132.

Binder W, Machelska H, Mousa S, et al.: Analgesic and antiinflammatory effects of two novel kappa-opioid peptides. Anesthesiology. 2001; 94(6): 1034-1044.

Caterina M, Schumacher M, Tominaga M, et al.: The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature. 1997; 389(6653): 816-824.

Kilo S, Harding-Rose C, Hargreaves K, et al.: Peripheral CGRP release as a marker for neurogenic inflammation: A model system for the study of neuropeptide secretion in rat paw skin. Pain. 1997; 73(2): 201-207.

LaMotte R, Lundberg L, Torebjörk H: Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol. 1992; 448: 749-764.

Ko M, Butelman E, Woods J: The role of peripheral mu opioid receptors in the modulation of capsaicin-induced thermal nociception in rhesus monkeys. J Pharmacol Exp Ther. 1998; 286(1): 150-156.

Ko M, Butelman E, Woods J: Activation of peripheral kappa opioid receptors inhibits capsaicin-induced thermal nociception in rhesus monkeys. J Pharmacol Exp Ther. 1999; 289(1): 378-385.

Hunter J, Leighton G, Meecham K, et al.: CI-977, a novel and selective agonist for the kappa-opioid receptor. Br J Pharmacol. 1990; 101(1): 183-189.

Vonvoigtlander P, Lewis R: Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid. J Pharmacol Exp Ther. 1988; 246(1): 259-262.

Pande A, Pyke R, Greiner M, et al.: Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. Clin Neuropharmacol. 1996; 19(5): 451-456.

Reece P, Sedman A, Rose S, et al.: Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J Clin Pharmacol. 1994; 34(11): 1126-1132.

Di Chiara G, Imperato A: Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther. 1988; 244(3): 1067-1080.

Donzanti B, Althaus J, Payson M, et al.: Kappa agonist-induced reduction in dopamine release: Site of action and tolerance. Res Commun Chem Pathol Pharmacol. 1992; 78(2): 193-210.

Barber A, Bartoszyk G, Bender H, et al.: A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br J Pharmacol. 1994; 113(4): 1317-1327.

Camilleri M: Novel pharmacology: Asimadoline, a kappaopioid agonist, and visceral sensation. Neurogastroenterol Motil. 2008; 20(9): 971-979.

Dooley C, Ny P, Bidlack J, et al.: Selective ligands for the mu, delta, and kappa opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library. J Biol Chem. 1998; 273(30): 18848-18856.

Chavkin C, James I, Goldstein A: Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science. 1982; 215(4531): 413-415.

Goldstein A, Tachibana S, Lowney L, et al.: Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA. 1979; 76(12): 6666-6670.

Vanderah T, Schteingart C, Trojnar J, et al.: FE200041 (DPhe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity. J Pharmacol Exp Ther. 2004; 310(1): 326-333.

Wisniewski B, Perlemuter G, Buffet C: Acute hepatitis following intravenous buprenorphine injection as a substitute drug in a drug-addict. Gastroenterol Clin Biol. 2001; 25(3): 328-329.

Vanderah T, Largent-Milnes T, Lai J, et al.: Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors. Eur J Pharmacol. 2008; 583(1): 62-72.

Arendt-Nielsen L, Olesen A, Staahl C, et al.: Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: Selective effect on visceral pain. Anesthesiology. 2009; 111(3): 616-624.

Fraitag B, Homerin M, Hecketsweiler P: Double-blind doseresponse multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia. Dig Dis Sci. 1994; 39(5): 1072-1077.

Delvaux M, Frexinos J: A European approach to irritable bowel syndrome management. Can J Gastroenterol. 1999; 13 (Suppl A): 85A-88A.

Allescher H, Ahmad S, Classen M, et al.: Interaction of trimebutine and Jo-1196 (fedotozine) with opioid receptors in the canine ileum. J Pharmacol Exp Ther. 1991; 257(2): 836-842.

Lai J, Ma S, Zhu R, et al.: Pharmacological characterization of the cloned kappa opioid receptor as a kappa 1b subtype. Neuroreport. 1994; 5(16): 2161-2164.

Eisenach J, Carpenter R, Curry R: Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain. 2003; 101(1-2): 89-95.

Delvaux M, Beck A, Jacob J, et al.: Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2004; 20(2): 237-246.

Szarka L, Camilleri M, Burton D, et al.: Efficacy of ondemand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007; 5(11): 1268-1275.

Mangel A, Bornstein J, Hamm L, et al.: Clinical trial: Asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2008; 28(2): 239-249.

Kabli N, Cahill C: Anti-allodynic effects of peripheral delta opioid receptors in neuropathic pain. Pain. 2007; 127(1-2): 84-93.

Obara I, Parkitna J, Korostynski M, et al.: Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain. Pain. 2009; 141(3): 283-291.

Reynolds L, Rauck R, Webster L, et al.: Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. Pain. 2004; 110(1-2): 182-188.

van Dorp E, Morariu A, Dahan A: Morphine-6-glucuronide: Potency and safety compared with morphine. Expert Opin Pharmacother. 2008; 9(11): 1955-1961.

Labuz D, Mousa S, Schäfer M, et al.: Relative contribution of peripheral versus central opioid receptors to antinociception. Brain Res. 2007; 1160: 30-38.

Stein C, Comisel K, Haimerl E, et al.: Analgesic effect of intraarticular morphine after arthroscopic knee surgery. N Engl J Med. 1991; 325(16): 1123-1126.

Kalso E, Tramèr M, Carroll D, et al.: Pain relief from intraarticular morphine after knee surgery: A qualitative systematic review. Pain. 1997; 71(2): 127-134.

Gupta A, Bodin L, Holmström B, et al.: A systematic review of the peripheral analgesic effects of intraarticular morphine. Anesth Analg. 2001; 93(3): 761-770.

Kalso E, Smith L, McQuay H, et al.: No pain, no gain: Clinical excellence and scientific rigour–Lessons learned from IA morphine. Pain. 2002; 98(3): 269-275.

Likar R, Schäfer M, Paulak F, et al.: Intraarticular morphine analgesia in chronic pain patients with osteoarthritis. Anesth Analg. 1997; 84(6): 1313-1317.

Likar R, Sittl R, Gragger K, et al.: Peripheral morphine analgesia in dental surgery. Pain. 1998; 76(1-2): 145-150.

Guan Y, Johanek L, Hartke T, et al.: Peripherally acting muopioid receptor agonist attenuates neuropathic pain in rats after L5 spinal nerve injury. Pain. 2008; 138(2): 318-329.

Shinoda K, Hruby V, Porreca F: Antihyperalgesic effects of loperamide in a model of rat neuropathic pain are mediated by peripheral delta-opioid receptors. Neurosci Lett. 2007; 411(2): 143-146.

Nozaki-Taguchi N, Shutoh M, Shimoyama N: Potential utility of peripherally applied loperamide in oral chronic graft-versushost disease related pain. Jpn J Clin Oncol. 2008; 38(12): 857-860.

Modalen A, Quiding H, Frey J, et al.: A novel molecule (frakefamide) with peripheral opioid properties: The effects on resting ventilation compared with morphine and placebo. Anesth Analg. 2005; 100(3): 713-717 (Table of Contents).

Shook J, Watkins W, Camporesi E: Differential roles of opioid receptors in respiration, respiratory disease, and opiateinduced respiratory depression. Am Rev Respir Dis. 1990; 142(4): 895-909.

Do Carmo G, Polt R, Bilsky E, et al.: Behavioral pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys. J Pharmacol Exp Ther. 2008; 326(3): 939-948.

Whiteside G, Harrison J, Pearson M, et al.: DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity. II. In vivo pharmacological characterization in the rat. J Pharmacol Exp Ther. 2004; 310(2): 793-799.

Seltzer Z, Dubner R, Shir Y: A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990; 43(2): 205-218.

Bileviciute-Ljungar I, Spetea M, Guo Y, et al.: Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation. J Pharmacol Exp Ther. 2006; 317(1): 220-227.

Ibrahim M, Porreca F, Lai J, et al.: CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA. 2005; 102(8): 3093-3098.

Rittner H, Brack A, Stein C: Pain and the immune system. Br J Anaesth. 2008; 101(1): 40-44.

Stein C, Clark J, Oh U, et al.: Peripheral mechanisms of pain and analgesia. Brain Res Rev. 2009; 60(1): 90-113.

Wilson S, Yeomans D: Virally mediated delivery of enkephalin and other neuropeptide transgenes in experimental pain models. Ann N Y Acad Sci. 2002; 971: 515-521.

Jensen R, Tiirikainen M, You L, et al.: Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. Anticancer Res. 2003; 23(3B): 2281-2289.

Zhang G, Mohammad H, Peper B, et al.: Enhanced peripheral analgesia using virally mediated gene transfer of the muopioid receptor in mice. Anesthesiology. 2008; 108(2): 305-313.